0001104659-23-004913.txt : 20230119 0001104659-23-004913.hdr.sgml : 20230119 20230119130830 ACCESSION NUMBER: 0001104659-23-004913 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230118 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230119 DATE AS OF CHANGE: 20230119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DIGITAL HEALTH ACQUISITION CORP. CENTRAL INDEX KEY: 0001864531 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 862970927 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41015 FILM NUMBER: 23536808 BUSINESS ADDRESS: STREET 1: 980 N FEDERAL HWY STREET 2: #304 CITY: BOCA RATON STATE: FL ZIP: 33432 BUSINESS PHONE: 5616727068 MAIL ADDRESS: STREET 1: 980 N FEDERAL HWY STREET 2: #304 CITY: BOCA RATON STATE: FL ZIP: 33432 8-K 1 tm2222551d11_8k.htm FORM 8-K
0001864531 false 0001864531 2023-01-18 2023-01-18 0001864531 dhacu:UnitsEachConsistingOfOneShareOfCommonStockAndOneRedeemableWarrantMember 2023-01-18 2023-01-18 0001864531 us-gaap:CommonStockMember 2023-01-18 2023-01-18 0001864531 dhacu:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOfDollar11.50Member 2023-01-18 2023-01-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): January 18, 2023

 

Digital Health Acquisition Corp.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41015   86-2970927

(State or other jurisdiction
of incorporation)

 

  (Commission
File Number)
  (IRS Employer
Identification No.)

980 N Federal Hwy #304

Boca Raton, FL 33432

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (561) 672-7068

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each
exchange on which
registered
Units, each consisting of one share of Common Stock and one Redeemable Warrant   DHACU   The Nasdaq Stock Market LLC
         
Common Stock, par value $0.0001 per share   DHAC   The Nasdaq Stock Market LLC
         
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50   DHACW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

As previously disclosed in its Current Report on Form 8-K filed on October 7, 2022 (the “Current Report”), in connection, and concurrently, with the execution of the Second Amended and Restated Business Combination Agreement, dated as of October 6, 2022, by and among the Company, DHAC Merger Sub I, Inc., DHAC Merger Sub II, Inc., VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc. (as amended, the “Business Combination Agreement”), Digital Health Acquisition Corp. (“DHAC” or the “Company”) entered into an Amended and Restated Securities Purchase Agreement, dated as of October 6, 2022 (the “PIPE SPA”) with certain accredited investors (the “PIPE Investors”). Pursuant to Section 4(o) of the PIPE SPA, the PIPE Investors have a participation right, but not an obligation, in subsequent offerings of the Company’s equity securities. Prior to the closing of the transactions contemplated by the Business Combination Agreement (the “Business Combination), the Company intends to offer the PIPE Investors the right to purchase up to an additional $2,000,000 of shares of its Series A Preferred Stock (the “Additional PIPE Shares”) and accompanying warrants on the same terms and conditions as provided in the PIPE SPA in accordance with and pursuant to Section 4(o) of the PIPE SPA (the “Additional PIPE Offering”).

 

On January 18, 2023, the Company entered into a backstop agreement (the “Backstop Agreement”) with Digital Health Sponsor LLC, a Delaware limited liability company (the “Sponsor”), pursuant to which the Sponsor committed to purchase any and all of such Additional PIPE Shares and accompanying warrants that remain unpurchased by the PIPE Investors in the Additional PIPE Offering (the “Remaining Securities”) at the same purchase price and on the same terms and conditions of the Additional PIPE Offering (the “Backstop Commitment”).

 

The Backstop Agreement contains customary representations, warranties, and agreements of the Company and the Sponsor and is subject to customary closing conditions and termination rights. If the conditions to the consummation of the Backstop Commitment contemplated by the Backstop Agreement are triggered, the closing of the sale of the Remaining Securities is expected to occur substantially concurrently with the closing of the transactions contemplated by the PIPE SPA.

 

Capitalized terms used but not otherwise defined in this Current Report on Form 8-K have the meanings given to such terms in the Backstop Agreement.

 

The Backstop Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K and the foregoing description is qualified in its entirety by reference to the full text of the Backstop Agreement.

 

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any security nor shall there be any sale of these securities in any state in which such offer, solicitation or sales would be unlawful prior to registration or qualification under the securities laws of any such state.

 

 

 

Exhibit 9.01. Financial Statements and Exhibits.

 

(d)

 

Exhibit No.   Description
     
10.1   Backstop Agreement, dated as of January 18, 2023, by and among Digital Health Acquisition Corp. and Digital Health Sponsor LLC
     
104   Cover Page Interactive Data File (embedded in the cover page formatted in Inline XBRL)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: January 19, 2023  
   
DIGITAL HEALTH ACQUISITION CORP.  
   
By: /s/ Scott Wolf  
Name:   Scott Wolf  
Title: Chief Executive Officer and Chairman  

 

 

EX-10.1 2 tm2222551d11_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

BACKSTOP AGREEMENT

 

This Backstop Agreement (the “Agreement”) is made as of January 18, 2023 by and between Digital Health Acquisition Corp., a Delaware corporation (the “Company”), and Digital Health Sponsor LLC, a Delaware limited liability company (“Sponsor”). Except as otherwise indicated herein, capitalized terms used herein are defined in Section 9 hereof.

 

WHEREAS, the Company seeks to consummate a proposed business combination (the “Business Combination”) in accordance with terms and conditions set forth in that certain Second Amended and Restated Business Combination Agreement, dated as of October 6, 2022, by and among the Company, DHAC Merger Sub I, Inc., DHAC Merger Sub II, Inc., VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc. (as amended, the “Business Combination Agreement”);

 

WHEREAS, concurrently with entry into the Business Combination Agreement, the Company has entered into an Amended and Restated Securities Purchase Agreement, dated as of October 6, 2022 (the “PIPE SPA”) with the investors party thereto (the “PIPE Investors”), pursuant to which the PIPE Investors have committed to purchase an aggregate of $8,000,000 of shares of Series A Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), of the Company, together with accompanying warrants to purchase certain shares of the common stock of the Company (the “PIPE Financing”) concurrent with the closing of the Business Combination;

 

WHEREAS, pursuant to Section 4(o) of the PIPE SPA, the PIPE Investors have a participation right in, among other things, subsequent offerings of the Company’s equity securities;

 

WHEREAS, on or prior to the closing of the Business Combination, the Company intends to offer the PIPE Investors the right to purchase up to an additional $2,000,000 of shares of Series A Preferred Stock (the “Additional PIPE Shares”) on the same terms and conditions as provided in the PIPE SPA in accordance with and pursuant to Section 4(o) of the PIPE SPA (the “Additional PIPE Offering”);

 

WHEREAS, the PIPE Investors are under no obligation to purchase the Additional PIPE Shares or to participate in the Additional PIPE Offering; and

 

WHEREAS, in the event that the PIPE Investors elect not to purchase all of the Additional PIPE Shares (after giving effect to the terms and conditions of Section 4(o) of the SPA), Sponsor has committed to purchase any and all of such Additional PIPE Shares that remain unpurchased in the Additional PIPE Offering (the “Remaining Shares”) at the same purchase price and on the same terms and conditions of the Additional PIPE Offering (the “Backstop Commitment”).

 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

 

Section 1. Additional PIPE Offering. Prior to the closing of the Business Combination, the Company intends to offer the PIPE Investors the right to purchase all or a portion of the Additional PIPE Shares in the Additional PIPE Offering on the same terms and conditions as provided in the PIPE Financing pursuant to Section 4(o) of the PIPE SPA (the “Subsequent Placement Offer”).

 

 

 

 

Section 2. Backstop Commitment. After the expiration of the Subsequent Placement Offer, to the extent the PIPE Investors elect not to purchase all of the Additional PIPE Shares in the Additional PIPE Offering (after giving effect to the terms and conditions of Section 4(o) of the SPA), Sponsor agrees to purchase any and all Remaining Shares at the same purchase price and on the same terms and conditions of the Additional PIPE Offering, subject, in each case, to Company obtaining all required consents to consummate such Additional PIPE Offering.

 

Section 3. The Closing. The Sponsor’s purchase of the Remaining Shares, if applicable, shall take place concurrent with the closing of the PIPE Financing (the “Closing”). At such Closing, if applicable, the Company shall deliver to Sponsor the certificates evidencing the shares of Series A Preferred Stock purchased pursuant to Section 2, and Sponsor shall deliver to the Company a cashier’s check or wire transfer of immediately available funds to a bank designated by the Company the total purchase price of the Remaining Shares it purchased.

 

Section 4. Representations and Warranties of the Company. As a material inducement to the Sponsor to enter into this Agreement and purchase the Remaining Shares, the Company hereby represents and warrants that:

 

(a) Organization and Corporate Power. The Company is a corporation duly organized, validly existing and in good standing under the laws of Delaware and is qualified to do business in every jurisdiction in which its ownership of property or conduct of business requires it to qualify. The Company has all requisite corporate power and authority and all material licenses, permits and authorizations necessary to own and operate its properties and to carry on its business as now conducted and presently proposed to be conducted, and all requisite corporate power and authority to carry out the transactions contemplated by this Agreement.

 

(b) Capital Stock. All of the issued and outstanding shares of capital stock of the Company have been duly and validly authorized and issued. All shares of Series A Preferred Stock to be purchased by Sponsor from the Company pursuant to Section 2 have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment therefor, will be validly issued, fully paid and nonassessable.

 

(c) Authorization; No Breach; Compliance with Laws. The execution, delivery and performance of this Agreement and any other agreement contemplated hereby to which the Company is a party have been duly authorized by the Company. The execution, delivery and performance of this Agreement by the Company and the consummation of the transactions contemplated hereby will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any of the property or assets of the Company is subject, (ii) result in any violation of the provisions of the charter or by-laws of the Company or (iii) result in any violation of any statute, including, without limitation, the Delaware General Corporation Law, or any order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its properties or assets. No consent, approval, authorization or order of, or filing or registration with, any such court or governmental agency or body is required for the execution, delivery and performance of this Agreement by the Company and the consummation of the transactions contemplated hereby.

 

2

 

 

(d) Broker’s Fees. There is no investment banker, broker, finder or other intermediary or advisor that has been retained by or is authorized to act on behalf of the Company or any of its Affiliates who might be entitled to any fee, commission or reimbursement of expenses as a result of consummation of the transactions contemplated hereby.

 

Section 5. Representations and Warranties of Sponsor. As a material inducement to the Company to enter into this Agreement, Sponsor hereby represents and warrants that:

 

(a) Organization and Corporate Power. Sponsor is a company duly organized, validly existing and in good standing and is qualified to do business in every jurisdiction in which its ownership of property or conduct of business requires it to qualify. Sponsor has all requisite company power and authority and all material licenses, permits and authorizations necessary to own and operate its properties and to carry on its business as now conducted and presently proposed to be conducted.

 

(b) Authorization; No Breach. The execution of this Agreement by Sponsor and the consummation by Sponsor of the transactions contemplated hereby will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which Sponsor is a party or by which Sponsor is bound or to which any of its property or assets is subject, nor will such actions result in any violation of the provisions of any statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over Sponsor or its property or assets in each case in a manner that would adversely impact Sponsor’s ability to purchase the Remaining Shares hereunder; and, except for such consents, approvals, authorizations, registrations or qualifications as may be required under applicable federal and state securities laws in connection with the purchase of the Remaining Shares, no consent, approval, authorization or order of, or filing or registration with, any such court or governmental agency or body is required for the execution, delivery and performance of this Agreement by Sponsor and the consummation by Sponsor of the transactions contemplated hereby in each case in a manner that would adversely impact Sponsor’s ability to purchase the Remaining Shares and perform its obligations hereunder.

 

(c) Investment Representations. Sponsor hereby represents that it will acquire the Remaining Shares, if any (the “Restricted Securities”) for its own account with the present intention of holding such securities for purposes of investment, and that it has no intention of selling such securities in a public distribution in violation of the federal securities laws or any applicable state securities laws. In addition, Sponsor hereby represents that it is sophisticated in financial matters and is able to evaluate the risks and benefits of the investment in the Restricted Securities.

 

(d) Accredited Investor Status. Sponsor is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D.

 

3

 

 

(e) Reliance on Exemptions. Sponsor understands that the Restricted Securities are being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and Sponsor’s compliance with, the representations and warranties of Sponsor set forth herein in order to determine the availability of such exemptions and the eligibility of Sponsor to acquire the Restricted Securities hereunder.

 

(f) Transfer or Resale. Sponsor understands that (i) the Restricted Securities have not been and are not being registered under the Securities Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) Sponsor shall have delivered to the Company an opinion of counsel, in form and substance reasonably satisfactory to the Company, to the effect that the Restricted Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) Sponsor provides the Company with reasonable assurance that the Restricted Securities can be sold, assigned or transferred pursuant to Rule 144 promulgated under the Securities Act or a successor rule thereto (“Rule 144”); (ii) any sale of Restricted Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of Restricted Securities under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations of the Commission thereunder.

 

(g) Legends. Sponsor understands that the certificates representing the Restricted Securities shall initially bear a restrictive legend in customary form (and a stop-transfer order may be placed against the transfer of such stock certificates).

 

(h) Broker’s Fees. There is no investment banker, broker, finder or other intermediary or advisor that has been retained by or is authorized to act on behalf of Sponsor who might be entitled to any fee, commission or reimbursement of expenses from either the Company or any of its Affiliates as a result of consummation of the transactions contemplated hereby.

 

Section 6. Conditions to Obligations of Each Party to Effect the Closing. The respective obligations of each party to consummate the transactions contemplated hereby are subject to the satisfaction on or prior to the Closing of each of the following conditions:

 

(a) All consents by third parties (government or otherwise) that are required for the consummation of the transactions contemplated hereby have been obtained on terms mutually agreeable to each party.

 

(b) No action, suit or proceeding shall be pending or threatened before any court or quasi-judicial or administrative agency of any jurisdiction or before any arbitrator wherein an unfavorable judgment, decree, injunction, order or ruling would prevent the performance of this agreement or any of the transactions contemplated, declare unlawful the transactions contemplated by this Agreement or cause such transactions to be rescinded.

 

4

 

 

Section 7. Conditions to Obligations of the Company to Effect the Closing. Subject to Section 6 above, the obligations of the Company to consummate the transactions contemplated hereby are subject to each of the representations and warranties of Sponsor contained in this Agreement being true and correct in all material respects as of the date hereof and at and as of the date of the Closing as if made at and as of such time, except that, to the extent such representations and warranties address matters only as of a particular date, such representations and warranties shall, to such extent, be true and correct in all material respects at and as of such particular date as if made at and as of such particular date.

 

Section 8. Conditions to Obligations of Sponsor to Effect the Closing. Subject to Section 6 above, the obligations of Sponsor to consummate the transactions contemplated hereby and to purchase the Remaining Shares are subject to each of the representations and warranties of the Company contained in this Agreement being true and correct in all material respects as of the date hereof and at and as of the date of the Closing as if made at and as of such time, except that, to the extent such representations and warranties address matters only as of a particular date, such representations and warranties shall, to such extent, be true and correct in all material respects at and as of such particular date as if made at and as of such particular date.

 

Section 9. Definitions. For the purposes of this Agreement, the following terms have the meanings set forth below:

 

Affiliate” means, with respect to any Person, any other Person directly or indirectly controlling, controlled by or under direct or indirect common control with such Person. For purposes of this definition, “control” when used with respect to any specified Person means the power to direct or cause the direction of the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise, and the terms “controlling” and “controlled” have meanings correlative of the foregoing.

 

Person” means an individual, a partnership, a corporation, a limited liability company, association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.

 

Securities Act” means the Securities Act of 1933, as amended, or any similar federal law then in force.

 

Section 10. Termination. This Agreement may be terminated at any time prior to the Closing, as follows:

 

(a) by mutual written consent of the Company and Sponsor;

 

(b) by either the Company or Sponsor if any governmental entity shall institute any suit or action challenging the validity or legality of, or seeking to restrain the consummation of, the transactions contemplated by this Agreement;

 

(c) by the Company, in the event Sponsor has breached any representation, warranty, or covenant contained in this Agreement, in any material respect, provided that the Company has notified Sponsor of the breach, and the breach has continued without cure for a period of 15 days after the notice of such breach or for such longer period so long as such breach is curable by Sponsor through the exercise of its reasonable efforts, and Sponsor continues to exercise such reasonable efforts; and

 

5

 

 

(d) by Sponsor, in the event that the Company has breached any representation, warranty, or covenant contained in this Agreement, in any material respect, provided that Sponsor has notified the Company of the breach, and the breach has continued without cure for a period of 15 days after the notice of such breach or for such longer period so long as such breach is curable by the Company through the exercise of its reasonable efforts, and the Company continues to exercise such reasonable efforts.

 

Section 11. Miscellaneous.

 

(a) Successors and Assigns. All covenants and agreements in this Agreement by or on behalf of any of the parties hereto will bind and inure to the benefit of the respective successors and assigns of the parties hereto whether so expressed or not; provided that neither this Agreement nor any of the rights, interests, or obligations hereunder may be assigned by any party without the prior written consent of the other party.

 

(b) Survival of Representations and Warranties. All representations and warranties contained herein or made in writing by any party in connection herewith shall survive the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby.

 

(c) Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

 

(d) Construction. Whenever the context requires, each term stated in either the singular or the plural shall include the singular and the plural, and pronouns stated in either the masculine, the feminine or the neuter gender shall include the masculine, feminine and neuter. All references to Sections and Paragraphs refer to sections and paragraphs of this Agreement. The use of the word “including” in this Agreement shall be by way of example rather than limitation.

 

(e) Amendment and Waiver. The provisions of this Agreement may be amended and waived only with the prior written consent of the parties hereto.

 

(f) Counterparts; Facsimile Signature. This Agreement may be executed simultaneously in two or more counterparts, any one of which need not contain the signatures of more than one party, but all such counterparts taken together shall constitute one and the same Agreement. This Agreement may be executed by facsimile signature.

 

6

 

 

(g) Governing Law. This Agreement will be governed in all respects by the laws of the State of Delaware, without regard to the principles of conflicts of law of such state.

 

(h) Notices. All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given when delivered personally to the recipient, sent to the recipient by reputable express courier service (charges prepaid) or mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid.

 

[Signature page follows]

 

 

7

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Backstop Agreement on the date first written above.

 

  Digital Health Acquisition Corp.
   
  By: /s/ Scott Wolf
  Name: Scott Wolf
  Title: Chief Executive Officer
   
  Digital Health Sponsor LLC
   
  By: /s/ Lawrence Sands
  Name: Lawrence Sands
  Title: Manager

 

8

 

EX-101.SCH 3 dhacu-20230118.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 dhacu-20230118_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 dhacu-20230118_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units, each consisting of one share of Common Stock and one Redeemable Warrant [Member] Common Stock [Member] Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Units, each consisting of one share of Common Stock and one Redeemable Warrant [Member] Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 EX-101.PRE 6 dhacu-20230118_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Jan. 18, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 18, 2023
Entity File Number 001-41015
Entity Registrant Name Digital Health Acquisition Corp.
Entity Central Index Key 0001864531
Entity Tax Identification Number 86-2970927
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 980 N Federal Hwy #304
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33432
City Area Code 561
Local Phone Number 672-7068
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of Common Stock and one Redeemable Warrant [Member]  
Title of 12(b) Security Units, each consisting of one share of Common Stock and one Redeemable Warrant
Trading Symbol DHACU
Security Exchange Name NASDAQ
Common Stock [Member]  
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol DHAC
Security Exchange Name NASDAQ
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 [Member]  
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50
Trading Symbol DHACW
Security Exchange Name NASDAQ
XML 8 tm2222551d11_8k_htm.xml IDEA: XBRL DOCUMENT 0001864531 2023-01-18 2023-01-18 0001864531 dhacu:UnitsEachConsistingOfOneShareOfCommonStockAndOneRedeemableWarrantMember 2023-01-18 2023-01-18 0001864531 us-gaap:CommonStockMember 2023-01-18 2023-01-18 0001864531 dhacu:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOfDollar11.50Member 2023-01-18 2023-01-18 iso4217:USD shares iso4217:USD shares 0001864531 false 8-K 2023-01-18 Digital Health Acquisition Corp. DE 001-41015 86-2970927 980 N Federal Hwy #304 Boca Raton FL 33432 561 672-7068 false false false false Units, each consisting of one share of Common Stock and one Redeemable Warrant DHACU NASDAQ Common Stock, par value $0.0001 per share DHAC NASDAQ Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 DHACW NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 4 23 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://digitalhealthacquisitioncorp.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2222551d11_8k.htm dhacu-20230118.xsd dhacu-20230118_def.xml dhacu-20230118_lab.xml dhacu-20230118_pre.xml tm2222551d11_ex10-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2222551d11_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 29 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "dhacu-20230118_def.xml" ] }, "inline": { "local": [ "tm2222551d11_8k.htm" ] }, "labelLink": { "local": [ "dhacu-20230118_lab.xml" ] }, "presentationLink": { "local": [ "dhacu-20230118_pre.xml" ] }, "schema": { "local": [ "dhacu-20230118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 2, "memberStandard": 1, "nsprefix": "dhacu", "nsuri": "http://digitalhealthacquisitioncorp.com/20230118", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2222551d11_8k.htm", "contextRef": "From2023-01-18to2023-01-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://digitalhealthacquisitioncorp.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2222551d11_8k.htm", "contextRef": "From2023-01-18to2023-01-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dhacu_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOfDollar11.50Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50", "label": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 [Member]" } } }, "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOfDollar11.50Member", "nsuri": "http://digitalhealthacquisitioncorp.com/20230118", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "dhacu_UnitsEachConsistingOfOneShareOfCommonStockAndOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units, each consisting of one share of Common Stock and one Redeemable Warrant [Member]", "label": "Units, each consisting of one share of Common Stock and one Redeemable Warrant [Member]" } } }, "localname": "UnitsEachConsistingOfOneShareOfCommonStockAndOneRedeemableWarrantMember", "nsuri": "http://digitalhealthacquisitioncorp.com/20230118", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://digitalhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-004913-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-004913-xbrl.zip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Š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end